Lista de obras - Angela Vidal-Jordana - Dominio Público Uruguay

A validation study of manual atrophy measures in patients with Multiple Sclerosis

artículo científico publicado en 2020

Activation-induced cell death in T lymphocytes from multiple sclerosis patients

artículo científico publicado en 2014

Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score

artículo científico publicado en 2020

An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.

artículo científico publicado en 2016

Biomarkers in multiple sclerosis: an update for 2014

artículo científico publicado en 2014

Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics

artículo científico publicado en 2016

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

artículo científico publicado en 2017

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

artículo científico publicado en 2014

COVID-19 in MS patients: susceptibility, severity risk factors and serological response

scientific article published on 19 December 2020

Characteristics of morphologic macular abnormalities in neuroimmunology practice.

artículo científico publicado en 2017

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

artículo científico publicado en 2016

Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis

artículo científico publicado en 2013

Comment on 'isolated bilateral horizontal gaze palsy as first manifestation of multiple sclerosis' by Stefan Kipfer and David W Crook

artículo científico publicado en 2014

Comment on: 'Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients'.

artículo científico publicado en 2013

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis

artículo científico publicado en 2016

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

artículo científico publicado en 2015

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

artículo científico publicado en 2017

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

artículo científico publicado en 2013

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

artículo científico publicado en 2018

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

artículo científico publicado en 2016

Lesion topographies in multiple sclerosis diagnosis: A reappraisal

artículo científico publicado en 2017

Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis

scientific article published on 16 April 2014

Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images

artículo científico publicado en 2016

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis

scientific article published on 01 March 2019

Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.

artículo científico publicado en 2017

Multiple sclerosis: clinical aspects

artículo científico publicado en 2018

Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision

artículo científico publicado en 2012

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.

artículo científico publicado en 2014

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome

artículo científico publicado en 2018

Neurofilament light chain level is a weak risk factor for the development of MS.

artículo científico publicado en 2016

New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis

artículo científico publicado en 2018

Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials

artículo científico publicado en 2020

Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability

scientific article published on 30 June 2020

Predictive value of early brain atrophy on response in patients treated with interferon β

artículo científico publicado en 2015

Radiologically isolated syndrome: 5-year risk for an initial clinical event

artículo científico publicado en 2014

Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study

scientific article published on 01 July 2019

Risk acceptance in multiple sclerosis patients on natalizumab treatment.

artículo científico publicado en 2013

Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis

artículo científico publicado en 2015

SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis

scientific article published on 29 August 2012

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

artículo científico publicado en 2015

Significant clinical worsening after natalizumab withdrawal: Predictive factors

article

Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis

artículo científico publicado en 2018

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor

artículo científico publicado en 2017

TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients

artículo científico publicado en 2013

The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS

artículo científico publicado en 2019

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

artículo científico publicado en 2018

Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

artículo científico publicado en 2015

Treatment of multiple sclerosis - success from bench to bedside

artículo científico publicado en 2019

Value of NMO-IgG determination at the time of presentation as CIS

artículo científico publicado en 2012

[Headache and immigration. A study in the outpatient department of the Hospital de la Santa Creu i Sant Pau in Barcelona]

artículo científico publicado en 2011

[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?]

artículo científico publicado en 2011

Lista de obras de Angela Vidal-Jordana

A validation study of manual atrophy measures in patients with Multiple Sclerosis

Activation-induced cell death in T lymphocytes from multiple sclerosis patients

Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score

An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.

Biomarkers in multiple sclerosis: an update for 2014

Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

COVID-19 in MS patients: susceptibility, severity risk factors and serological response

Characteristics of morphologic macular abnormalities in neuroimmunology practice.

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis

Comment on 'isolated bilateral horizontal gaze palsy as first manifestation of multiple sclerosis' by Stefan Kipfer and David W Crook

Comment on: 'Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients'.

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

Lesion topographies in multiple sclerosis diagnosis: A reappraisal

Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis

Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis

Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.

Multiple sclerosis: clinical aspects

Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome

Neurofilament light chain level is a weak risk factor for the development of MS.

New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis

Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials

Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability

Predictive value of early brain atrophy on response in patients treated with interferon β

Radiologically isolated syndrome: 5-year risk for an initial clinical event

Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study

Risk acceptance in multiple sclerosis patients on natalizumab treatment.

Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis

SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

Significant clinical worsening after natalizumab withdrawal: Predictive factors

Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor

TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients

The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

Treatment of multiple sclerosis - success from bench to bedside

Value of NMO-IgG determination at the time of presentation as CIS

[Headache and immigration. A study in the outpatient department of the Hospital de la Santa Creu i Sant Pau in Barcelona]

[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?]